Vimovo (naproxen and esomeprazole magnesium)

VIMOVO is a fixed-dose combination of enteric coated naproxen, a pain-relieving nonsteroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a proton pump inhibitor (PPI). VIMOVO modified-release tablets is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient¹.

VIMOVO was co-developed by AstraZeneca and POZEN Inc. and approved by the US Food and Drug Administration on April 30, 2010.

¹ While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of VIMOVO may not be the same in different countries. Information on this site is derived from the Summary of Product Characteristics (SPC) for VIMOVO in the UK. Please refer to your local Prescribing Information for full details.